Application progress of BNP and NT-proBNP in neonates

doi:10.3969/j.issn.1673-8640.2023.06.003

Abstract

Abstract:

B-type natriuretic peptide（BNP） and N-terminal pro-B-type natriuretic peptide（NT-proBNP） are blood markers secreted by cardiomyocytes and sensitive indicators reflecting cardiac structure and function. There is no consensus on the reference ranges of plasma levels of BNP and NT-proBNP in neonates，but many studies have explored the application in the diagnosis assessment，therapeutic monitoring and prognostic evaluation for neonatal cardiovascular diseases. This review mainly summarizes the above aspects in order to provide guidance for clinical application.

Key words: B-type natriuretic peptide, N-terminal pro-B-type natriuretic peptide, Neonate, Cardiovascular disease, Therapeutic monitoring, Prognosis

CLC Number:

R446.1

YIN Ya, PAN Yuan, ZHOU Hongwei, SHEN Wei. Application progress of BNP and NT-proBNP in neonates[J]. Laboratory Medicine, 2023, 38(6): 518-523.

Figures/Tables 3

References 57

[1]	MARKOVIC-SOVTIC G, KOSUTIC J, JANKOVIC B, et al. N-terminal pro-brain natriuretic peptide in the assessment of respiratory distress in term neonates[J]. Pediatr Int, 2014, 56(3):373-377. DOI URL
[2]	DANIELS L B, MAISEL A S. Natriureticpeptides[J]. J Am Coll Cardiol, 2007, 50(25):2357-2368. DOI URL
[3]	GOETZE J P, BRUNEAU B G, RAMOS H R, et al. Cardiac natriuretic peptides[J]. Nat Rev Cardiol, 2020, 17(11):698-717. DOI
[4]	PAVASINI R, TAVAZZI G, BISCAGLIA S, et al. Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease:systematic review and meta-analysis[J]. Chron Respir Dis, 2017, 14(2):117-126. DOI URL
[5]	XIE H, HUO Y, CHEN Q, et al. Application of B-type natriuretic peptide in neonatal diseases[J]. Front Pediatr, 2021, 9:767173. DOI URL
[6]	HALL C. NT-proBNP:the mechanism behind the marker[J]. J Card Fail, 2005, 11(5 Suppl):S81-S83. DOI URL
[7]	OGAWA T, VATTA M, BRUNEAU B G, et al. Characterization of natriuretic peptide production by adult heart atria[J]. Am J Physiol, 1999, 276(6):H1977-H1986.
[8]	MA K K, OGAWA T, DE BOLD A J. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase[J]. J Mol Cell Cardiol, 2004, 36(4):505-513. PMID
[9]	XIAO P, LI H, LI X, et al. Analytical barriers in clinical B-type natriuretic peptide measurement and the promising analytical methods based on mass spectrometry technology[J]. Clin Chem Lab Med, 2019, 57(7):954-966. DOI PMID
[10]	NIMJEE S M, RUSCONI C P, SULLENGER B A. Aptamers:an emerging class of therapeutics[J]. Annu Rev Med, 2005, 56:555-583. DOI URL
[11]	YANDLE T G, RICHARDS A M. B-type natriuretic peptide circulating forms:Analytical and bioactivity issues[J]. Clin Chim Acta, 2015, 448:195-205. DOI URL
[12]	HAWKRIDGE A M, HEUBLEIN D M, BERGEN H R 3rd, et al. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide(BNP-32)in severe human heart failure[J]. Proc Natl Acad Sci U S A, 2005, 102(48):17442-17447. DOI URL
[13]	MAISEL A S, KRISHNASWAMY P, NOWAK R M, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure[J]. N Engl J Med, 2002, 347(3):161-167. DOI URL
[14]	MCDONAGH T A, METRA M, ADAMO M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021, 42(36):3599-3726. DOI URL
[15]	CANTINOTTI M, STORTI S, PARRI M S, et al. Reference values for plasma B-type natriuretic peptide in the first days of life[J]. Clin Chem, 2009, 55(7):1438-1440. DOI PMID
[16]	SOLDIN S J, SOLDIN O P, BOYAJIAN A J, et al. Pediatric brain natriuretic peptide and N-terminal pro-brain natriuretic peptide reference intervals[J]. Clin Chim Acta, 2006, 366(1-2):304-308. DOI PMID
[17]	RODRIGUEZ D, GARCIA-RIVAS G, LARESGOITI-SERVITJE E, et al. B-type natriuretic peptide reference interval of newborns from healthy and pre-eclamptic women:a prospective,multicentre,cross-sectional study[J]. BMJ Open, 2018, 8(10):e022562. DOI URL
[18]	GAROFOLI F, MANNARINO S, MONTANARI L, et al. Variation of B-type natriuretic peptide concentrations and intrauterine growth restriction:mother,fetus and newborn[J]. J Biol RegulHomeost Agents, 2012, 26(4):733-739.
[19]	TAUBER K A, DOYLE R, GRANINA E, et al. B-type natriuretic peptide levels normalise in preterm infants without a patent ductus arteriosus by the fifth postnatal day[J]. Acta Paediatr, 2016, 105(8):e352-e355. DOI URL
[20]	张茜, 罗成汉, 时赞扬, 等. 早期早产儿血浆N末端脑钠肽参考值范围[J]. 中华实用儿科临床杂志, 2013, 28(2):98-101.
[21]	MIREA L, SANKARAN K, SESHIA M, et al. Treatment of patent ductus arteriosus and neonatal mortality/morbidities:adjustment for treatment selection bias[J]. J Pediatr, 2012, 161(4):689-694.e1. DOI URL
[22]	SEHGAL A, MCNAMARA P J. The ductus arteriosus:a refined approach![J]. Semin Perinatol, 2012, 36(2):105-113. DOI URL
[23]	MONTANER RAMÓN A, GALVE PRADEL Z, FERNÁNDEZ ESPUELAS C, et al. Usefulness of brain natriuretic propeptide in the diagnosis and management of patent ductus arteriosus[J]. An Pediatr(Barc), 2017, 86(6):321-328.
[24]	KULKARNI M, GOKULAKRISHNAN G, PRICE J, et al. Diagnosing significant PDA using natriuretic peptides in preterm neonates:a systematic review[J]. Pediatrics, 2015, 135(2):e510-e525. DOI URL
[25]	CUI Q, LIU X, SU G, et al. Change and clinical significance of serum cortisol,BNP,and PGE-2 levels in premature infants with patent ductus arteriosus[J]. TranslPediatr, 2021, 10(10):2573-2578.
[26]	PARRA-BRAVO J R, VALDOVINOS-PONCE M T, GARCÍA H, et al. B-type brain natriuretic peptide as marker of hemodynamicoverload of the patent ductus arteriosus in the preterm infant[J]. Arch Cardiol Mex, 2021.
[27]	MINE K, OHASHI A, TSUJI S, et al. B-type natriuretic peptide for assessment of haemodynamically significant patent ductus arteriosus in premature infants[J]. Acta Paediatr, 2013, 102(8):e347-e352. DOI URL
[28]	KIM J S, SHIM E J. B-type natriuretic Peptide assay for the diagnosis and prognosis of patent ductus arteriosus in preterm infants[J]. Korean Circ J, 2012, 42(3):192-196. DOI PMID
[29]	KALRA V K, DEBARI V A, ZAUK A, et al. Point-of-care testing for B-type natriuretic peptide in premature neonates with patent ductus arteriosus[J]. Ann Clin Lab Sci, 2011, 41(2):131-137. PMID
[30]	PERMYAKOVA A V, PORODIKOV A, KUCHUMOV A G, et al. Discriminant analysis of main prognostic factors associated with hemodynamically significant PDA:Apgar score,Silverman-Anderson score,and NT-pro-BNP level[J]. J Clin Med, 2021, 10(16):3729. DOI URL
[31]	CAMBONIE G, DUPUY A M, COMBES C, et al. Can a clinical decision rule help ductus arteriosus management in preterm neonates?[J]. Acta Paediatr, 2012, 101(5):e213-e218. DOI URL
[32]	BUDDHE S, DHUPER S, KIM R, et al. NT-proBNP levels improve the ability of predicting a hemodynamically significant patent ductus arteriosus in very low-birth-weight infants[J]. J Clin Neonatol, 2012, 1(2):82-86. DOI URL
[33]	MARTINOVICI D, VANDEN EIJNDEN S, UNGER P, et al. Early NT-proBNP is able to predict spontaneous closure of patent ductus arteriosus in preterm neonates,but not the need of its treatment[J]. PediatrCardiol, 2011, 32(7):953-957.
[34]	GUDMUNDSDOTTIR A, BARTOCCI M, PICARD O, et al. Early N-terminal pro B-type natriuretic peptide(NTproBNP)plasma values and associations with patent ductus arteriosus closure and treatment-an echocardiography study of extremely preterm infants[J]. J Clin Med, 2022, 11(3):667. DOI URL
[35]	JEONG H A, SHIN J, KIM E, et al. Correlation of B-type natriuretic peptide levels and echocardiographic parameters in preterm infants with patent ductus arteriosus[J]. Korean J Pediatr, 2016, 59(4):183-189. DOI PMID
[36]	OH S H, LEE B S, JUNG E, et al. Plasma B-type natriuretic peptide cannot predict treatment response to ibuprofen in preterm infants with patent ductus arteriosus[J]. Sci Rep, 2020, 10(1):4430. DOI PMID
[37]	SHIN J, LEE E H, LEE J H, et al. Individualized ibuprofen treatment using serial B-type natriuretic peptide measurement for symptomatic patent ductus arteriosus in very preterm infants[J]. Korean J Pediatr, 2017, 60(6):175-180. DOI PMID
[38]	FU L, ZHANG X. Correlation between changes in brain natriuretic peptide and echocardiographic features in persistent pulmonary hypertension of newborn[J]. J Matern Fetal Neonatal Med, 2020, 33(13):2176-2180. DOI PMID
[39]	LAMMERS A E, HISLOP A A, HAWORTH S G. Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension[J]. Int J Cardiol, 2009, 135(1):21-26. DOI PMID
[40]	PARTRIDGE E A, HANNA B D, RINTOUL N E, et al. Brain-type natriuretic peptide levels correlate with pulmonary hypertension and requirement for extracorporeal membrane oxygenation in congenital diaphragmatic hernia[J]. J Pediatr Surg, 2015, 50(2):263-266. DOI PMID
[41]	SHAH N, NATARAJAN G, AGGARWAL S. B-type natriuretic peptide:biomarker of persistent pulmonary hypertension of the newborn?[J]. Am J Perinatol, 2015, 32(11):1045-1049. DOI URL
[42]	AVITABILE C M, ANSEMS S, WANG Y, et al. Accuracy of brain natriuretic peptide for diagnosing pulmonary hypertension in severe bronchopulmonary dysplasia[J]. Neonatology, 2019, 116(2):147-153. DOI URL
[43]	REYNOLDS E W, ELLINGTON J G, VRANICAR M, et al. Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn[J]. Pediatrics, 2004, 114(5):1297-1304. PMID
[44]	LEYA F S, ARAB D, JOYAL D, et al. The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy[J]. J Am Coll Cardiol, 2005, 45(11):1900-1902. PMID
[45]	BABUIN L, ALEGRIA J R, OH J K, et al. Brain natriuretic peptide levels in constrictive pericarditis and restrictive cardiomyopathy[J]. J Am Coll Cardiol, 2006, 47(7):1489-1491. PMID
[46]	DEN BOER S L, RIZOPOULOS D, DU MARCHIE SARVAAS G J, et al. Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements to predict cardiac death in acute and chronic dilated cardiomyopathy in children[J]. Am J Cardiol, 2016, 118(11):1723-1729. DOI PMID
[47]	MEYER S, GORTNER L, GOTTSCHLING S, et al. Cardiogenic shock in a neonate with enterovirus myocarditis[J]. Klin Padiatr, 2009, 221(7):444-447. DOI PMID
[48]	MEDAR S S, HSU D T, USHAY H M, et al. Serial measurement of amino-terminal pro-B-type natriuretic peptide predicts adverse cardiovascular outcome in children with primary myocardial dysfunction and acute decompensated heart failure[J]. Pediatr Crit Care Med, 2015, 16(6):529-534. DOI URL
[49]	CANTINOTTI M, LAW Y, VITTORINI S, et al. The potential and limitations of plasma BNP measurement in the diagnosis,prognosis,and management of children with heart failure due to congenital cardiac disease:an update[J]. Heart Fail Rev, 2014, 19(6):727-742. DOI URL
[50]	AHMED A M, MOHAMED N A E, ABDELHAMID E M, et al. N-terminal pro-brain natriuretic peptide as a biomarker for differentiating cardiac and pulmonary disease in term neonates with respiratory distress[J]. J Saudi Heart Assoc, 2020, 32(1):65-70.
[51]	DAVLOUROS P A, KARATZA A A, XANTHOPOULOU I, et al. Diagnostic role of plasma BNP levels in neonates with signs of congenital heart disease[J]. Int J Cardiol, 2011, 147(1):42-46. DOI PMID
[52]	CANTINOTTI M, STORTI S, RIPOLI A, et al. Diagnostic accuracy of B-type natriuretic hormone for congenital heart disease in the first month of life[J]. Clin Chem Lab Med, 2010, 48(9):1333-1338. DOI PMID
[53]	LAW Y M, HOYER A W, RELLER M D, et al. Accuracy of plasma B-type natriuretic peptide to diagnose significant cardiovascular disease in children:the Better Not Pout Children! Study[J]. J Am Coll Cardiol, 2009, 54(15):1467-1475. DOI URL
[54]	MANGAT J, CARTER C, RILEY G, et al. The clinical utility of brain natriuretic peptide in paediatric left ventricular failure[J]. Eur J Heart Fail, 2009, 11(1):48-52. DOI PMID
[55]	PRICE J F, THOMAS A K, GRENIER M, et al. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction[J]. Circulation, 2006, 114(10):1063-1069. PMID
[56]	CANTINOTTI M, WALTERS H L, CROCETTI M, et al. BNP in children with congenital cardiac disease:is there now sufficient evidence for its routine use?[J]. Cardiol Young, 2015, 25(3):424-437. DOI URL
[57]	VOLPE M, BATTISTONI A, RUBATTU S. Natriuretic peptides in heart failure:current achievements and future perspectives[J]. Int J Cardiol, 2019, 281:186-189. DOI URL

参考文献	发表年	国家	生物标志物	例数/例	胎龄/周	日龄/d	BNP临界值/（pg/mL）	敏感性/%	特异性/%
[25]	2021年	中国	BNP	67	28~32	3	①	75.6	73.1
[26]	2021年	墨西哥	BNP	29	< 32	3~5	486.5	81.0	92.0
[27]	2013年	日本	BNP	46	<33	1~2	550.0	83.0	86.0
[28]	2012年	韩国	BNP	28	<37	4	412.0	100.0	95.0
[29]	2011年	美国	BNP	52	<34	3~7	122.5	100.0	100.0
[30]	2021年	美国	NT-proBNP	99	27.6±2.55	3	8 500.0	84.0	86.0
[31]	2012年	法国	NT-proBNP	140	<32	1~3	8 500.0	90.0	76.0
[32]	2012年	美国	NT-proBNP	69	27	3~5	5 900.0	96.0	90.0
[33]	2011年	比利时	NT-proBNP	31	<32	2/4	10 000.0/5 000.0	89.0/91.0	100.0/100.0

参考文献	发表年	国家	生物标志物	例数/例	胎龄/周	日龄/d	BNP临界值/（pg/mL）	敏感性/%	特异性/%
[25]	2021年	中国	BNP	67	28~32	3	①	75.6	73.1
[26]	2021年	墨西哥	BNP	29	< 32	3~5	486.5	81.0	92.0
[27]	2013年	日本	BNP	46	<33	1~2	550.0	83.0	86.0
[28]	2012年	韩国	BNP	28	<37	4	412.0	100.0	95.0
[29]	2011年	美国	BNP	52	<34	3~7	122.5	100.0	100.0
[30]	2021年	美国	NT-proBNP	99	27.6±2.55	3	8 500.0	84.0	86.0
[31]	2012年	法国	NT-proBNP	140	<32	1~3	8 500.0	90.0	76.0
[32]	2012年	美国	NT-proBNP	69	27	3~5	5 900.0	96.0	90.0
[33]	2011年	比利时	NT-proBNP	31	<32	2/4	10 000.0/5 000.0	89.0/91.0	100.0/100.0

参考文献	发表年	国家	生物标志物	例数/例	胎龄/周	年龄/h	BNP 临界值/（pg/mL）	敏感性/%	特异性/%
[42]	2019年	美国	BNP	128	<32	24	130	50.0	92.0
[43]	2004年	美国	BNP	47	37.4~38.5	24	550	83.0	100.0

参考文献	发表年	国家	生物标志物	例数/例	胎龄/周	年龄/h	BNP 临界值/（pg/mL）	敏感性/%	特异性/%
[42]	2019年	美国	BNP	128	<32	24	130	50.0	92.0
[43]	2004年	美国	BNP	47	37.4~38.5	24	550	83.0	100.0

参考文献	发表年	国家	生物标志物	疾病	例数/例	胎龄/周	日龄/d	BNP/（pg/mL）	敏感性/%	特异性/%
[50]	2020年	沙特阿拉伯	NT-pro BNP	CHD	20	37.20±1.36	30.0	24.5	66.0	85.0
[51]	2011年	希腊	BNP	CHD	75	<37.00	0.5~2.0	132.5	93.1	100.0
[52]	2010年	德国	BNP	CHD	152	35.00~42.00	0.0~3.0	417.0	84.0	66.0
							4.0~30.0	206.0	91.0	80.0
[53]	2009年	美国	BNP	CHD	42	36.00	1.0	170.0	94.0	73.0